CAJ | 학술논문

目的：观察替吉奥在晚期胃癌患者维持治疗的疗效、临床受益率和不良反应。方法：42例初诊为晚期胃癌的患者，经过氟尿嘧啶类组成的联合化疗方案化疗4~6周期，化疗后部分缓解（PR）或稳定（SD）的患者，被随机分为替吉奥维持组和观察组。替吉奥维持组采用替吉奥单药口服，连用4周，停药2周，6周为一个周期。观察组不予任何治疗。治疗2个周期后评价疗效。结果：替吉奥维持组总有效率为42.9%，临床受益率为85.7%，中位疾病进展时间为4.5个月，中位总生存期为7.5个月；观察组总有效率为33.3%，临床受益率为80.9%，中位疾病进展时间为3.0个月，中位总生存期为6.5个月；两组近期疗效、中位疾病进展时间比较差异有统计学意义（P "0.05），临床受益率、不良反应的发生率、总生存时间组间比较差异无统计学意义（P ﹥0.05）。结论：替吉奥在晚期胃癌患者维持治疗疗效肯定、可取得较好的生存质量，毒副作用小。
목적：관찰체길오재만기위암환자유지치료적료효、림상수익솔화불량반응。방법：42례초진위만기위암적환자，경과불뇨밀정류조성적연합화료방안화료4~6주기，화료후부분완해（PR）혹은정（SD）적환자，피수궤분위체길오유지조화관찰조。체길오유지조채용체길오단약구복，련용4주，정약2주，6주위일개주기。관찰조불여임하치료。치료2개주기후평개료효。결과：체길오유지조총유효솔위42.9%，림상수익솔위85.7%，중위질병진전시간위4.5개월，중위총생존기위7.5개월；관찰조총유효솔위33.3%，림상수익솔위80.9%，중위질병진전시간위3.0개월，중위총생존기위6.5개월；량조근기료효、중위질병진전시간비교차이유통계학의의（P "0.05），림상수익솔、불량반응적발생솔、총생존시간조간비교차이무통계학의의（P ﹥0.05）。결론：체길오재만기위암환자유지치료료효긍정、가취득교호적생존질량，독부작용소。
Objective:To evaluate the clinical efficacy,the clinical benefit response and adverse reaction of S-1 in the ma-intenance therapy of patients with advanced gastric cancer. Methods:Forty-two patients with advanced gastric cancer un-derwent combined chemotherapy of fluorouracil in 4 ~ 6 cycles. The PR or SD patients were divided into S-1 group and observation group after chemotherapy. For the S-1 group,6 weeks constituted a cycle. Among the cycle,4 weeks for S-1 taking,2 weeks for withdrawl. In the observation group,no treatment was performed. Curative efficacy was assessed af-ter 2 cycles. Results:The total response rate of S-1 group was 42. 9% and 33. 3% of the observation group and the TTP were 4. 5 months and 3. 0 months respectively;there were significant difference between the two groups(P " 0. 05). The clinical benefit response of S-1 group was 85. 7% and 80. 9% of the observation group and the MST were 7. 5 months and 6. 5 months respectively. There were no difference between the two groups(P ﹥ 0. 05). Conclusions:The S-1 shows positive effect for patients with advanced gastric cancer in the maintenance therapy. It can achieve a better quality of life and small side effects for the patients.